[Good News] Research Achievement of Doctor Wang Fengmei to Shine at AASLD International Academic S
[Good News] Research Achievement of Doctor Wang Fengmei to Shine at AASLD International Academic Stage
Recently, the research abstract by Wang Fengmei, Assistant to the President of Wuwei Cancer Hospital and Director of the Fourth Department of Liver Diseases at the Hepatobiliary Center, has been accepted by the AASLD (American Association for the Study of Liver Diseases) Annual Meeting and will be presented in poster format. This recognition is not only a personal honor for Director Wang Fengmei but also a solid milestone for the Hepatobiliary Center in the field of liver disease research. As a premier global academic event in hepatology, AASLD maintains rigorous standards for selecting academic contributions. This acceptance fully demonstrates the exceptional expertise and innovative spirit of Director Wang Fengmei and her team in liver disease research.
Over the years, Director Wang Fengmei has consistently adhered to a rigorous academic attitude and dedicated herself to advancing liver disease research. The presentation of this research on an international academic stage marks high recognition of her professional capabilities and brings widespread attention from the global academic community to the hospital. Inspired by Director Wang’s exemplary work, the Hepatobiliary Center will continue to achieve breakthrough results in liver disease prevention and treatment, delivering higher-quality medical services to patients and contributing significantly to public health.
Poster Presentation
Expert Profile
Wuwei Medical Science Institute Hepatobiliary Center, now a National Demonstration Base for Hepatobiliary Disease Prevention and Treatment Technology, comprehensively conducts clinical and research work in hepatology, including:
● Liver protection, antiviral therapy, artificial liver treatment;
● Surgical operations, interventional and minimally invasive procedures;
● Iodine seed implantation, targeted and immunotherapy;
● Cellular immunotherapy, and stem cell transplantation.
As one of China’s few specialized centers capable of integrated diagnosis, treatment, and holistic management of hepatobiliary diseases, the center:
1.Undertakes multiple real-world research projects and national public-benefit initiatives;
2.Establishes expert consultation platforms for complex and severe liver diseases, collaborating with renowned domestic and international specialists;
3.Pioneers Gansu Province’s first Diabetes-Liver Disease Co-Management Center, benefiting patients with hepatobiliary diseases (especially critical cases) and liver-related metabolic disorders (e.g., diabetes, fatty liver).